Lyell ImmunopharmaLYEL
Recorded

Lyell Immunopharma Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Steven WilleySenior Biotech Analyst

Okay. I'm Stephen Willey, one of the Senior Biotech Analysts here at Stifel, and very glad to have with us from Lyell, CEO Lynn Seely. Lynn, thanks for joining us. A lot to talk about. Any opening statements you want to make before we jump into Q&A?

Lynn SeelyCEO

Sure. I'm happy to introduce the company.

Steven WilleySenior Biotech Analyst

First, Steve, thanks Your mic there, yeah.

Lynn SeelyCEO

First, thanks for hosting us. For those who are not as familiar with Lyell Immunopharma, we are a clinical-stage cell therapy company developing next-generation CAR T-cell therapies for patients with hematologic malignancies or solid tumors. Our lead program is ronde-cel, which is a dual-targeting CD19/CD20 CAR T-cell therapy, which is really very meticulously designed to bring more complete responses and more durable complete responses for patients with large B-cell lymphoma. We're currently in two pivotal trials. We have a third or later line pivotal trial we call PiNACLE, and we're going to be presenting data from that trial in an oral presentation at ASH coming up here in just a few weeks. We'll have the final pivotal data from that trial mid-next year, with BLA submission next year. We're barreling forward towards approval. We're very excited about that.

Lynn SeelyCEO

In addition, we have a first-of-its-kind head-to-head trial, a randomized controlled trial in second-line large B-cell lymphoma, where patients are being randomized either to ronde-cel or to investigator's choice of the two approved CD19 CAR T-cell therapies, YESCARTA or BREYANZI. We will be presenting new data from a second-line cohort, not this randomized controlled trial, but a second-line cohort from our phase I/II study at ASH as well. A lot going on. Excited to talk to you about it.

Steven WilleySenior Biotech Analyst

All right. That is great. I definitely want to spend probably most of the time here on ronde-cel, just given the ASH data. But maybe before we dig into that, you talked about the ability of ronde-cel to expand the breadth and depth of responses that you are seeing. Can you just talk a little bit about how ronde-cel is differentiated from standard of care CD19 CAR T, and how you are achieving that breadth and depth of response from an engineering design and then also manufacturing perspective?

Lynn SeelyCEO

Sure. Design, of course, is very important, as is manufacturing. So ronde-cel is a single tandem CAR that expresses binding sites for both CD19 or CD20, so it is full potency at CD19 or CD20. This is really important because some malignant B cells are low or no CD19, so you can imagine they will not respond to CD19 CARs, where with both either/or antigen, you can really drive more complete responses. With two antigens, it becomes much harder for malignant cells to escape this antigen, or the CAR T-cell therapy, so we get more persistence. But that is not all. This program was really designed to manufacture cells in a very specific way. The field has really aligned around the fact that naive T cells in the cell product really drive better outcomes.

Lynn SeelyCEO

So our product is very specifically manufactured to enrich the high majority of cells in our final cell product to be naive or central memory T cells. We do this by a very simple process during manufacturing of CD62L enrichment. We are the only company that is doing that, and we find that is a very controlled way to get the naive T cells during manufacturing. So we think this is really, both of these things coming together, the dual targeting and the CD62L selection for naive cells, is sort of the secret sauce of ronde-cel. I would be remiss to say that we also at Lyell invested in our own manufacturing center many years ago, and so all of our product is manufactured there. We are running our commercial manufacturing process as we speak, and we can make more than 3,000 cell doses, so get well into launch.

Lynn SeelyCEO

I think this idea of a very rationally designed cell product and then a very carefully manufactured next-generation product is really important for us.

Steven WilleySenior Biotech Analyst

One of the two ASH abstracts that were published, updated results from the registrational phase I/II PiNACLE trial. I think we are expecting top-line data middle part of next year.

Steven WilleySenior Biotech Analyst

That is correct. This is third line plus large B-cell lymphoma.

Steven WilleySenior Biotech Analyst

Historical efficacy benchmarks are very well established. Can you just highlight how the updated ronde-cel data appears to now be tracking relative to those benchmarks?

Lynn SeelyCEO

Sure. The two leading approved CD19 CARs are YESCARTA and BREYANZI. Both were first approved in the third or later line setting with single-arm trials, very similar to what we're doing. There, the data are quite similar to one another. Overall response rates for YESCARTA and BREYANZI are 72%, 73%. Complete response rates for YESCARTA and BREYANZI are 51%, 54%, and the median progression-free survival is six to seven months. That's sort of the standard of care. We're presenting data in the third or later line from our pivotal trial that is showing we have a 91% overall response rate, a 77% complete response rate, and I think what we're really pleased about is a median progression-free survival that is not reached. Last year, it was 18 months, and this year, it's now not reached and expected to be at least 24 months.

Lynn SeelyCEO

Really continuing to improve as the data mature.

Steven WilleySenior Biotech Analyst

Yeah. I thought your ability to replicate that 70%+ CR rate across a larger denominator of patients was important just for establishing confidence, I think, for investors. To your point, the durability here looks to be really interesting, right? I think there was a 12-month progression landmark in the abstract that was 63%, right? Again, the benchmark here is six or seven months in terms of median.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day